医学
小细胞肺癌
细胞毒性T细胞
肿瘤科
细胞毒性
肺
肺癌
癌症研究
化疗
免疫检查点
癌
细胞
免疫系统
封锁
内科学
小细胞癌
转录组
免疫学
免疫疗法
受体
基因
生物
体外
基因表达
生物化学
遗传学
作者
M. Campisi,M. Chen,P. Schol,M. Tarannum,J. Wolff,R. Romee,S. Rodig,D.A. Barbie,N.R. Mahadevan
标识
DOI:10.1016/j.jtho.2022.07.244
摘要
Small cell lung carcinoma (SCLC) comprises approximately 15% of all lung cancer cases and SCLC patients initially respond to cytotoxic chemotherapy, but resistance inevitably emerges. Despite recent incorporation of immune checkpoint blockade (ICB) into first line treatment, predictive biomarkers of response remain lacking and patients with SCLC continue to have a poor prognosis with limited treatment options. Notably, recent transcriptomic profiling of SCLC cell lines and patient samples has indicated significant inter-tumoral and intra-tumoral heterogeneity.
科研通智能强力驱动
Strongly Powered by AbleSci AI